MAPT and Alzheimer disease: There are at least 85 phosphorylation modification sites on tau, and some phosphorylated tau forms (e. g., p-tau181, p-tau217, and p-tau231) are significantly increased in the early stages of AD, implicating their contribution to disease progression and providing potential biomarkers for early diagnosis of AD49,.50